Form 4 for GANX Gain Therapeutics, Inc.
Accepted 2024-08-12 00:00:00 ET · period of report 2024-08-09 · accession 0001493152-24-031377 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-12 | 2024-08-09 | GANX | Islam Khalid | Executive COB, Dir | P - Purchase | $1.00 | +50.0K | 50.0K | New | +$50.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-09 | P | A | 50,000 | $1.00 | 50,000 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.9814 to $1.00 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |